Clinical trial
Prospective, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Subjects With Type II Diabetes
NCT02481141 is registered in ClinicalTrials.gov with SBI Pharmaceuticals Co, Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Subjects With Type II Diabetes
- Lead sponsor
- SBI Pharmaceuticals Co, Ltd.
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- July 31, 2014
- Completion date
- July 31, 2015
- Enrollment
- 53 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.